| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05943990 2019-004446-14 Details | 2024-03-18 Interventional | 1 | 5 | Cyclophosphamid… Fludarabine Liposarcoma Liposarcoma, My… Sarcoma Sarcoma, Synovi… Neoplasms | The study was terminated due to a change in GSK's R&D priorities. - | |||
| NCT05574712 Details | 2024-03-18 Interventional | 2 | 0 | Abiraterone Ace… Belzutifan Leuprolide Prostatic Neopl… Prostate Cancer | Principal Investigator has decided not to activate this trial. - | |||
| NCT05361915 Details | 2024-03-18 Interventional | 2 | - | Abivertinib Prostatic Neopl… Prostate Cancer Prostate Cancer… | Sorrento Therapeutics filed for chapter 11 bankruptcy. - | |||
| NCT05087914 Details | 2024-03-18 Interventional | 2 | 0 | Carbidopa Carbidopa, levo… Levodopa Naproxen Acute Pain Pain, Postopera… Bunionectomy Toe Fusion | Study was not started, therefore recruitment did not happen - | |||
| NCT05044429 Details | 2024-03-18 Interventional | 4 | 31 | Lidocaine Pain, Postopera… Kidney Transpla… | Lack of interest for continuing on by PI and issues with IRB - | |||
| NCT04382898 2018-004321-86 Details | 2024-03-18 Interventional | 1/2 | 75 | Cemiplimab Prostatic Neopl… Prostate Cancer | Sponsor decision - | |||
| NCT03596073 Details | 2024-03-18 Interventional | 1 | 43 | Calcipotriene Petrolatum Breast Neoplasm… Breast Cancer | Interim analysis did not show the required cytokine induction by topical calcipotriene to
justify continuation of the trial - | |||
| NCT03098355 Details | 2024-03-18 Interventional | 1/2 | 0 | Interleukin-2 Leukemia, B-Cel… Leukemia, Lymph… B-Cell Leukemia B-Cell Lymphoma | The company did not offer the appropriate CART services. - | |||
| NCT02696291 Details | 2024-03-18 Interventional | 1 | 7 | Pharmaceutical … Infections Virus Diseases Viral Infection | Product development halted for business reasons. Study was terminated after Cohort 1. While no analysis was performed for change from baseline for physical exam (PE, a secondary endpoint), any change from baseline PE was reported/analyzed as an AE. AUC0-inf (secondary endpoint) was not calculated. | |||
| NCT01311674 Details | 2024-03-18 Interventional | 3 | 141 | Vaccines Hepatitis Hepatitis B Healthy Volunte… | Prematurely terminated due to failure to meet study objectives. This reporting only covers the interim analysis data collected within a 12 month period between enrolment of the first subject on 9 September 2009 and the interim analysis report cut off date of 1 September 2010. | |||
| NCT06312800 Details | 2024-03-15 Interventional | 2 | 0 | Acamprosate Methazolamide Essential Tremo… Tremor | Study was never initiated. - | |||
| NCT06077669 Details | 2024-03-15 Interventional | 4 | 0 | Methylphenidate ADHD | Study withdrawn in IRB by PI - | |||
| NCT05472506 Details | 2024-03-15 Interventional | 1 | 0 | Nivolumab Carcinoma Head and Neck N… Squamous Cell C… Head Cancer Head Cancer Nec… Head and Neck C… Head and Neck S… Neck Cancer Neck Carcinoma | Sponsor Decision - | |||
| NCT05193370 Details | 2024-03-15 Interventional | 4 | 0 | Angiotensin II Angiotensinogen Arginine Vasopr… Giapreza Vasopressins Shock Shock, Septic Septic Shock | Funding and protocol changes. Replaced with new pilot trial. - | |||
| NCT04729348 Details | 2024-03-15 Interventional | 2 | 10 | Lenvatinib Pembrolizumab Meningeal Carci… Neoplasm Metast… Neoplasms Leptomeningeal … Solid Tumor Solid Tumor, Ad… | Planned interim analysis - | |||
| NCT04498468 Details | 2024-03-15 Interventional | 4 | 77 | Dexamethasone Dry Eye Syndrom… Keratoconjuncti… Dry Eye | The study was terminated prematurely due to administrative reasons; loss of several research
personnel. Because of strict eligibility criteria, the investigators anticipated delays in
completing enrollment and therefore decided to terminate early. The study was not able to enroll its planned sample size. VAS, while consistently used in measuring clinical symptoms of illnesses, is limited in that patients may encounter difficulties in rating their symptomology, especially if the participants feel ambivalent towards the VAS prompts. | |||
| NCT04410042 Details | 2024-03-15 Interventional | 3 | 15 | Tranexamic Acid Bone Neoplasms Cancer of the B… Limb Salvage | Per sponsor - | |||
| NCT03519308 Details | 2024-03-15 Interventional | 1 | 3 | Gemcitabine Nivolumab Paclitaxel Pancreatic Neop… Pancreatic Canc… | The accrual goal could not be met and the drug manufacturer pulled support - | |||
| NCT03463460 Details | 2024-03-15 Interventional | 2 | - | Pembrolizumab Sunitinib Carcinoma Thymoma Thymic Carcinom… | PI decision - | |||
| NCT02621021 Details | 2024-03-15 Interventional | 2 | 20 | Aldesleukin Cyclophosphamid… Fludarabine Pembrolizumab Melanoma | The team is revising the protocol design and has chosen to put the study on hold until those
changes are approved. - |